Brief: Solvonis Therapeutics Says NIDA To Fund Early Preclinical Evaluation Of Svn-015
Dec 3 (Reuters) - Solvonis Therapeutics PLC SVNS.L: NIDA TO FUND EARLY PRECLINICAL EVALUATION OF SVN-015 ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Solvonis Therapeutics
See all newsBrief: Solvonis Therapeutics Plans IND Submission For Phase 2B Trial Of SVN-2 In U.S.
Solvonis Therapeutic - Announces Positive Bridging Data Supporting
Solvonis Therapeutic - Notice of Annual General Meeting
RCS - Solvonis Therapeutic - CSO Speaks at National Research Meeting
Solvonis Therapeutic - Final Results